x

Cyclerion Therapeutics, Inc. (Nasdaq:CYCN)

Health Care/Life Sciences • Biotechnology
CIK 1755237
Company

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Address
Riverview II
245 First Street
18th floor
Cambridge, Massachusetts 02142
Employees
16
Stock Info
Close
$3.2000
Day Range
2.8984 - 3.0000
52 Week Range
1.7501 - 13.3380
Average volume
7.27K
Short Interest
26.84K (02/15/24)
% of Float Shorted
1.58%
Market Cap
$7.82M
Revenue
$1.63M
Net Income
-$44.08M
2020 Sales Growth
N/A
Rev. per Employee
$38.00K
P/E Ratio
N/A
EPS
-$11.7058
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
Director
Dina Katabi phD
Director
Michael J Higgins MBA
Director
Peter M Hecht PhD
Chairman
Errol B de Souza PhD
Independent Director
Steven E Hyman MD
Independent Director
Terrance G McGuire MBA
SEC filings
DateFormEvent
7 Aug, 2024 8-K
7 Aug, 2024 4
7 Aug, 2024 10-Q
12 Jul, 2024 SC 13G/A
14 Jun, 2024 8-K
7 May, 2024 10-Q
29 Apr, 2024 DEFA14A
29 Apr, 2024 DEF 14A
18 Apr, 2024 8-K
11 Mar, 2024 3
5 Mar, 2024 10-K
14 Feb, 2024 SC 13G/A
9 Feb, 2024 SC 13G/A
9 Feb, 2024 SC 13G/A
26 Jan, 2024 4
26 Jan, 2024 4
22 Jan, 2024 SC 13G/A
28 Dec, 2023 UPLOAD
12 Dec, 2023 CORRESP
11 Dec, 2023 3
7 Dec, 2023 3/A
7 Dec, 2023 3
5 Dec, 2023 SC 13D/A
4 Dec, 2023 8-K CEO Change
4 Dec, 2023 4
4 Dec, 2023 4
4 Dec, 2023 3
4 Dec, 2023 4
4 Dec, 2023 4
1 Dec, 2023 8-K
28 Nov, 2023 UPLOAD
24 Nov, 2023 8-K
13 Nov, 2023 10-Q
23 Oct, 2023 8-K
5 Sep, 2023 SC 13G
11 Aug, 2023 4
31 Jul, 2023 S-8
28 Jul, 2023 10-Q
19 Jul, 2023 8-K
12 Jul, 2023 8-K
27 Jun, 2023 8-K
9 Jun, 2023 PREM14A
1 Jun, 2023 8-K
25 May, 2023 8-K
25 May, 2023 D
23 May, 2023 SC 13D/A
22 May, 2023 4
15 May, 2023 8-K
12 May, 2023 10-Q
12 May, 2023 8-K
12 May, 2023 DEFA14A
12 May, 2023 SC 13D/A
3 Apr, 2023 DEFA14A
3 Apr, 2023 SC 13D/A
3 Apr, 2023 8-K
3 Apr, 2023 DEF 14A
22 Mar, 2023 PRE 14A
22 Mar, 2023 10-K
22 Mar, 2023 8-K
9 Feb, 2023 SC 13G/A
13 Jan, 2023 SC 13G
29 Nov, 2022 8-K
22 Nov, 2022 8-K
21 Nov, 2022 SC 13D/A
3 Nov, 2022 10-Q
21 Oct, 2022 SC 13D
6 Oct, 2022 8-K
30 Sep, 2022 8-K
10 Aug, 2022 S-8
9 Aug, 2022 8-K
9 Aug, 2022 10-Q
28 Jul, 2022 8-K
27 Jul, 2022 4/A
26 Jul, 2022 4
26 Jul, 2022 3
26 Jul, 2022 8-K
16 Jun, 2022 4
16 Jun, 2022 4
16 Jun, 2022 4
16 Jun, 2022 4
16 Jun, 2022 4
16 Jun, 2022 4
16 Jun, 2022 4
15 Jun, 2022 8-K
10 Jun, 2022 8-K
3 Jun, 2022 8-K
4 May, 2022 10-Q
4 May, 2022 8-K
26 Apr, 2022 DEF 14A
26 Apr, 2022 DEFA14A
24 Feb, 2022 10-K
24 Feb, 2022 8-K
11 Feb, 2022 SC 13G/A
11 Feb, 2022 SC 13G/A
9 Feb, 2022 SC 13G/A
9 Feb, 2022 SC 13G/A
24 Jan, 2022 4
24 Jan, 2022 4
24 Jan, 2022 4
24 Jan, 2022 4
10 Dec, 2021 4
10 Dec, 2021 4
10 Dec, 2021 4
9 Nov, 2021 8-K
9 Nov, 2021 10-Q
28 Oct, 2021 8-K
30 Sep, 2021 8-K
7 Sep, 2021 UPLOAD
27 Aug, 2021 10-Q/A
27 Aug, 2021 CORRESP
27 Aug, 2021 10-K/A
27 Aug, 2021 10-Q/A
24 Aug, 2021 UPLOAD
19 Aug, 2021 8-K CEO Change
30 Jul, 2021 S-8
29 Jul, 2021 8-K
29 Jul, 2021 10-Q
28 Jun, 2021 4
28 Jun, 2021 4
28 Jun, 2021 4
28 Jun, 2021 4
28 Jun, 2021 4
28 Jun, 2021 4
28 Jun, 2021 4
28 Jun, 2021 4
25 Jun, 2021 8-K
24 Jun, 2021 424B4
23 Jun, 2021 S-3/A
23 Jun, 2021 EFFECT
21 Jun, 2021 UPLOAD
21 Jun, 2021 CORRESP
17 Jun, 2021 D
16 Jun, 2021 S-3
7 Jun, 2021 4
7 Jun, 2021 4
7 Jun, 2021 4
7 Jun, 2021 SC 13D/A
4 Jun, 2021 8-K
19 May, 2021 3
14 May, 2021 SC 13D
10 May, 2021 4
6 May, 2021 4
4 May, 2021 8-K
30 Apr, 2021 10-Q
28 Apr, 2021 DEFA14A
28 Apr, 2021 DEF 14A
27 Apr, 2021 8-K
26 Apr, 2021 8-K
19 Mar, 2021 8-K/A
18 Mar, 2021 8-K
1 Mar, 2021 4
1 Mar, 2021 4
25 Feb, 2021 10-K
16 Feb, 2021 SC 13G/A
12 Feb, 2021 SC 13G
8 Feb, 2021 SC 13G/A
5 Feb, 2021 SC 13G/A
13 Jan, 2021 8-K
11 Jan, 2021 3
11 Jan, 2021 3
Last update:2024-03-06 13:21:43.949329

Sign Up to Subscribe